Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC

Despite the recent advance of consolidation durvalumab in the treatment of unresectable stage III NSCLC, not every patient benefits from durvalumab and the predictive markers of response have been difficult to identify. We performed a retrospective analysis of patients with unresectable stage III NS...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2021-05, Vol.16 (5), p.868-872
Main Authors: Hellyer, Jessica A., Aredo, Jacqueline V., Das, Millie, Ramchandran, Kavitha, Padda, Sukhmani K., Neal, Joel W., Wakelee, Heather A.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Durvalumab
EGFR
ErbB Receptors - genetics
ERBB2
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
PACIFIC
Prospective Studies
Retrospective Studies
Stage III
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the recent advance of consolidation durvalumab in the treatment of unresectable stage III NSCLC, not every patient benefits from durvalumab and the predictive markers of response have been difficult to identify. We performed a retrospective analysis of patients with unresectable stage III NSCLC treated with consolidation durvalumab after definitive chemoradiation from January 2018 to March 2020. A total of 36 patients with unresectable stage III NSCLC were treated with consolidation durvalumab. Of these patients, 14 had tumor mutations in the ERBB family including 11 EGFR and 3 ERBB2. The ERBB2/EGFR tumor mutation cohort was more likely to be nonsmokers; otherwise, the two groups were similar in age, sex, programmed death-ligand 1 expression, and type of previous chemotherapy regimen. Patients in the ERBB2/EGFR cohort had a significantly shorter disease-free survival compared with the EGFR or ERBB2 wild-type cohort (7.5 mo versus not reached, p = 0.04). Consolidation durvalumab seems to be less efficacious in patients with ERBB2/EGFR-mutant tumors. Future work should seek to evaluate this in the prospective setting and provide insight into the optimal treatment of ERBB2/EGFR-mutant stage III NSCLC.
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2020.12.020